🚀 VC round data is live in beta, check it out!
ACADIA Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for ACADIA Pharmaceuticals and similar public comparables like Viking Therapeutics, Kanghong Pharmaceutical, Corcept Therapeutics, Kangmei Pharmaceutical Co. and more.
ACADIA Pharmaceuticals Overview
About ACADIA Pharmaceuticals
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Founded
1993
HQ
Employees
654
Website
Financials (LTM)
EV
$3B
ACADIA Pharmaceuticals Financials
ACADIA Pharmaceuticals reported last 12-month revenue of $1B and EBITDA of $106M.
In the same LTM period, ACADIA Pharmaceuticals generated $1B in gross profit, $106M in EBITDA, and $318M in net income.
Revenue (LTM)
ACADIA Pharmaceuticals P&L
In the most recent fiscal year, ACADIA Pharmaceuticals reported revenue of $1B and EBITDA of $117M.
ACADIA Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $983M | XXX | XXX | XXX |
| Gross Margin | 92% | XXX | 92% | XXX | XXX | XXX |
| EBITDA | $106M | XXX | $117M | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 11% | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 10% | XXX | XXX | XXX |
| Net Profit | $318M | XXX | $391M | XXX | XXX | XXX |
| Net Margin | 29% | XXX | 37% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
ACADIA Pharmaceuticals Stock Performance
ACADIA Pharmaceuticals has current market cap of $4B, and enterprise value of $3B.
Market Cap Evolution
ACADIA Pharmaceuticals' stock price is $22.80.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $4B | 0.0% | XXX | XXX | XXX | $2.31 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialACADIA Pharmaceuticals Valuation Multiples
ACADIA Pharmaceuticals trades at 2.8x EV/Revenue multiple, and 28.8x EV/EBITDA.
EV / Revenue (LTM)
ACADIA Pharmaceuticals Financial Valuation Multiples
As of March 27, 2026, ACADIA Pharmaceuticals has market cap of $4B and EV of $3B.
Equity research analysts estimate ACADIA Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ACADIA Pharmaceuticals has a P/E ratio of 12.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 2.8x | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | 28.8x | XXX | 26.3x | XXX | XXX | XXX |
| EV/EBIT | 31.9x | XXX | 29.2x | XXX | XXX | XXX |
| EV/Gross Profit | 3.0x | XXX | 3.1x | XXX | XXX | XXX |
| P/E | 12.1x | XXX | 9.9x | XXX | XXX | XXX |
| EV/FCF | 19.7x | XXX | 26.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ACADIA Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
ACADIA Pharmaceuticals Margins & Growth Rates
ACADIA Pharmaceuticals' revenue in the last 12 month grew by 15%.
ACADIA Pharmaceuticals' revenue per employee in the last FY averaged $1.7M.
ACADIA Pharmaceuticals' rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ACADIA Pharmaceuticals' rule of X is 48% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
ACADIA Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | (23%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 25% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 48% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.7M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 52% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 31% | XXX | 31% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 82% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
ACADIA Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Mental Health Technology comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Viking Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Kanghong Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Corcept Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Kangmei Pharmaceutical Co. | XXX | XXX | XXX | XXX | XXX | XXX |
| ADMA Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ACADIA Pharmaceuticals M&A Activity
ACADIA Pharmaceuticals acquired XXX companies to date.
Last acquisition by ACADIA Pharmaceuticals was on XXXXXXXX, XXXXX. ACADIA Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by ACADIA Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialACADIA Pharmaceuticals Investment Activity
ACADIA Pharmaceuticals invested in XXX companies to date.
ACADIA Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. ACADIA Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by ACADIA Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ACADIA Pharmaceuticals
| When was ACADIA Pharmaceuticals founded? | ACADIA Pharmaceuticals was founded in 1993. |
| Where is ACADIA Pharmaceuticals headquartered? | ACADIA Pharmaceuticals is headquartered in United States. |
| How many employees does ACADIA Pharmaceuticals have? | As of today, ACADIA Pharmaceuticals has over 654 employees. |
| Who is the CEO of ACADIA Pharmaceuticals? | ACADIA Pharmaceuticals' CEO is Catherine Owen Adams. |
| Is ACADIA Pharmaceuticals publicly listed? | Yes, ACADIA Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of ACADIA Pharmaceuticals? | ACADIA Pharmaceuticals trades under ACAD ticker. |
| When did ACADIA Pharmaceuticals go public? | ACADIA Pharmaceuticals went public in 2004. |
| Who are competitors of ACADIA Pharmaceuticals? | ACADIA Pharmaceuticals main competitors are Viking Therapeutics, Kanghong Pharmaceutical, Corcept Therapeutics, Kangmei Pharmaceutical Co.. |
| What is the current market cap of ACADIA Pharmaceuticals? | ACADIA Pharmaceuticals' current market cap is $4B. |
| What is the current revenue of ACADIA Pharmaceuticals? | ACADIA Pharmaceuticals' last 12 months revenue is $1B. |
| What is the current revenue growth of ACADIA Pharmaceuticals? | ACADIA Pharmaceuticals revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of ACADIA Pharmaceuticals? | Current revenue multiple of ACADIA Pharmaceuticals is 2.8x. |
| Is ACADIA Pharmaceuticals profitable? | Yes, ACADIA Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ACADIA Pharmaceuticals? | ACADIA Pharmaceuticals' last 12 months EBITDA is $106M. |
| What is ACADIA Pharmaceuticals' EBITDA margin? | ACADIA Pharmaceuticals' last 12 months EBITDA margin is 10%. |
| What is the current EV/EBITDA multiple of ACADIA Pharmaceuticals? | Current EBITDA multiple of ACADIA Pharmaceuticals is 28.8x. |
| What is the current FCF of ACADIA Pharmaceuticals? | ACADIA Pharmaceuticals' last 12 months FCF is $156M. |
| What is ACADIA Pharmaceuticals' FCF margin? | ACADIA Pharmaceuticals' last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of ACADIA Pharmaceuticals? | Current FCF multiple of ACADIA Pharmaceuticals is 19.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.